Showing results (231-240 of 264) with videos related to

Sort By:
Pageof 27
Cancer Research and Treatment|November 6, 2025
Impact of Cell-of-Origin and MYC/BCL2 Status on the Risk of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell LymphomaChang-Hoon Lee, Ga-Young Song, Ho-Young Yhim, et al.
Oncotarget|November 8, 2017
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, et al.
Haematologica|June 11, 2026
The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 studyMihee Kim, Ho Cheol Jang, Jae-Sook Ahn, et al.
American Journal of Hematology|August 24, 2017
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapyHyungwoo Cho, Dok Hyun Yoon, Jung Bok Lee, et al.
Cancer Communications (London, England)|October 18, 2019
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
The American Journal of Gastroenterology|February 2, 2023
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneDo Young Kim, Yu Ri Kim, Cheolwon Suh, et al.
Cancers|February 13, 2026
Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 StudyJongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, et al.
Pageof 27